重组人可溶性血栓调节蛋白对脓毒症相关凝血病患者死亡率的影响:SCARLET随机临床试验
SCARLET试验是一项在26个国家159个ICU进行的随机、双盲、安慰剂对照、多国、多中心3期研究,纳入2012年10月至2018年3月期间入住参与ICU的脓毒症相关凝血病合并心血管和/或呼吸衰竭的成人患者。患者随机接受静脉推注或15分钟输注血栓调节蛋白0.06 mg/kg/d(最大6 mg/d)或匹配安慰剂,每日一次,共6天。主要终点28天全因死亡率在血栓调节蛋白组为26.8%(106/395),安慰剂组为29.4%(119/405),差异无统计学意义(P=0.32),绝对风险差2.55%(95%CI -3.68%至8.77%)。严重大出血不良事件发生率血栓调节蛋白组5.8%(23/396),安慰剂组4.0%(16/404)。
要点
- 在脓毒症相关凝血病合并心血管和/或呼吸衰竭的成人ICU患者中,重组人血栓调节蛋白0.06 mg/kg/d(最大6 mg/d)每日一次静脉给药共6天,28天全因死亡率26.8% vs 安慰剂29.4%,未达统计学显著差异(P=0.32)。
- 绝对风险差2.55%(95%CI -3.68%至8.77%),置信区间跨0,未显示获益。
- 严重大出血不良事件:血栓调节蛋白组5.8%(23/396) vs 安慰剂组4.0%(16/404)。
- 该研究为多国、多中心3期RCT,样本量816例随机化,800例纳入全分析集。
适用人群与场景
- 成人患者,入住参与研究的ICU,时间为2012年10月至2018年3月。
- 脓毒症相关凝血病,定义为国际标准化比值大于1.40且无其他已知病因,并且血小板计数在30至150×10⁹/L范围内或24小时内血小板计数下降大于30%。
- 同时合并心血管和/或呼吸衰竭。
诊断标准与关键阈值
- 脓毒症相关凝血病诊断标准:国际标准化比值大于1.40且无其他已知病因,同时血小板计数30至150×10⁹/L或24小时内血小板计数下降大于30%。
- 合并心血管和/或呼吸衰竭。
处置流程与药物剂量
- 血栓调节蛋白组:静脉推注或15分钟输注重组人血栓调节蛋白0.06 mg/kg/d(最大6 mg/d),每日一次,共6天。
- 对照组:匹配安慰剂,同样给药方式每日一次,共6天。
研究设计与关键结果
- 研究设计:随机、双盲、安慰剂对照、多国、多中心3期研究,在26个国家159个ICU进行。
- 样本量:816例随机化,800例完成研究并纳入全分析集(平均年龄60.7岁,男性437例[54.6%])。
- 主要终点:28天全因死亡率血栓调节蛋白组26.8%(106/395) vs 安慰剂组29.4%(119/405),P=0.32,绝对风险差2.55%(95%CI -3.68%至8.77%)。
- 严重大出血不良事件:血栓调节蛋白组5.8%(23/396) vs 安慰剂组4.0%(16/404);严重大出血定义:任何颅内出血、危及生命的出血、或研究者判定为严重且连续2天输注至少1440 mL(通常6单位)浓缩红细胞。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照、多国、多中心3期临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒症相关凝血病合并心血管和/或呼吸衰竭的成人ICU患者,与安慰剂相比,重组人血栓调节蛋白未显著降低28天全因死亡率,作者结论为未显著减少28天全因死亡率。
指南或共识出处
- SCARLET随机临床试验(NCT01598831),发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Previous research suggested that soluble human recombinant thrombomodulin may reduce mortality among patients with sepsis-associated coagulopathy.
OBJECTIVE: To determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality among patients with sepsis-associated coagulopathy.
DESIGN, SETTING, AND PARTICIPANTS: The SCARLET trial was a randomized, double-blind, placebo-controlled, multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 countries. All adult patients admitted to one of the participating intensive care units between October 2012 and March 2018 with sepsis-associated coagulopathy and concomitant cardiovascular and/or respiratory failure, defined as an international normalized ratio greater than 1.40 without other known etiology and a platelet count in the range of 30 to 150 × 109/L or a greater than 30% decrease in platelet count within 24 hours, were considered for inclusion. The final date of follow-up was February 28, 2019.
INTERVENTIONS: Patients with sepsis-associated coagulopathy were randomized and treated with an intravenous bolus or a 15-minute infusion of thrombomodulin (0.06 mg/kg/d [maximum, 6 mg/d]; n = 395) or matching placebo (n = 405) once daily for 6 days.
MAIN OUTCOME AND MEASURES: The primary end point was 28-day all-cause mortality.
RESULTS: Among 816 randomized patients, 800 (mean age, 60.7 years; 437 [54.6%] men) completed the study and were included in the full analysis set. In these patients, the 28-day all-cause mortality rate was not statistically significantly different between the thrombomodulin group and the placebo group (106 of 395 patients [26.8%] vs 119 of 405 patients [29.4%], respectively; P = .32). The absolute risk difference was 2.55% (95% CI, -3.68% to 8.77%). The incidence of serious major bleeding adverse events (defined as any intracranial hemorrhage; life-threatening bleeding; or bleeding event classified as serious by the investigator, with administration of at least 1440 mL [typically 6 units] of packed red blood cells over 2 consecutive days) was 23 of 396 patients (5.8%) in the thrombomodulin group and 16 of 404 (4.0%) in the placebo group.
CONCLUSIONS AND RELEVANCE: Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01598831.
参考来源
- Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019. PMID: 31104069. doi:10.1001/jama.2019.5358
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。